Literature DB >> 8867252

Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service.

Stefan Grond1, Detlev Zech, Christoph Diefenbach, Lukas Radbruch, Klaus A Lehmann.   

Abstract

Although pain assessment is a vital preliminary step towards the satisfactory control of cancer pain, data on the prevalence of different pain syndromes are rare. In a prospective study of 2266 cancer patients, we assessed localisations, aetiologies and pathophysiological mechanisms of the pain syndromes. Thirty percent of the patients presented with 1, 39% with 2 and 31% with 3 or more distinct pain syndromes. The majority of patients had pain caused by cancer (85%) or antineoplastic treatment (17%); 9% had pain related to cancer disease and 9% due to aetiologies unrelated to cancer. Pain could be classified as originating from nociceptors in bone (35%), soft tissue (45%) or visceral structures (33%) or otherwise as of an neuropathic origin (34%). In most patients, pain syndromes were located in the lower back (36%), abdominal region (27%), thoracic region (23%), lower limbs (21%), head (17%) and pelvic region (15%). The main pain syndrome was also coded according to the IASP Classification of Chronic Pain. Regions and systems affected by the main pain syndrome showed large variation depending on the site of cancer origin, whereas temporal characteristics, intensity and aetiology were not markedly influenced by the cancer site. The variety of pain syndromes evaluated in our patients confirms the importance of comprehensive pain assessment prior to treatment.

Entities:  

Mesh:

Year:  1996        PMID: 8867252     DOI: 10.1016/0304-3959(95)00076-3

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  59 in total

1.  Differences in pain location, intensity, and quality by pain pattern in outpatients with cancer.

Authors:  Srisuda Ngamkham; Janean E Holden; Diana J Wilkie
Journal:  Cancer Nurs       Date:  2011 May-Jun       Impact factor: 2.592

Review 2.  New Cancer Pain Treatment Options.

Authors:  Kenneth D Candido; Teresa M Kusper; Nebojsa Nick Knezevic
Journal:  Curr Pain Headache Rep       Date:  2017-02

3.  Pain Quality by Location in Outpatients with Cancer.

Authors:  Judith M Schlaeger; Li-Chueh Weng; Hsiu-Li Huang; Hsiu-Hsin Tsai; Miho Takayama; Srisuda Ngamkham; Yingwei Yao; Diana J Wilkie
Journal:  Pain Manag Nurs       Date:  2019-05-31       Impact factor: 1.929

Review 4.  Access to opioid analgesics and pain relief for patients with cancer.

Authors:  Shalini Dalal; Eduardo Bruera
Journal:  Nat Rev Clin Oncol       Date:  2013-01-15       Impact factor: 66.675

Review 5.  Pain management in the home.

Authors:  Nessa Coyle
Journal:  Curr Pain Headache Rep       Date:  2005-08

6.  Clinical and genetic factors related to cancer-induced bone pain and bone pain relief.

Authors:  Emanuela Scarpi; Daniele Calistri; Pål Klepstad; Stein Kaasa; Frank Skorpen; Ragnhild Habberstad; Oriana Nanni; Dino Amadori; Marco Maltoni
Journal:  Oncologist       Date:  2014-10-23

7.  Development of a novel location-based assessment of sensory symptoms in cancer patients: preliminary reliability and validity assessment.

Authors:  Adam R Burkey; Peter A Kanetsky
Journal:  J Pain Symptom Manage       Date:  2008-12-06       Impact factor: 3.612

8.  Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy.

Authors:  Joel B Epstein; Diana J Wilkie; Dena J Fischer; Young-Ok Kim; Dana Villines
Journal:  Head Neck Oncol       Date:  2009-07-14

9.  Are Religious Coping and Pain Perception Related Together? Assessment in Iranian Cancer Patients.

Authors:  Amir Hossein Goudarzian; Azar Jafari; Sima Beik; Masoumeh Bagheri Nesami
Journal:  J Relig Health       Date:  2018-12

10.  Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group.

Authors:  G Apolone; O Corli; A Caraceni; E Negri; S Deandrea; M Montanari; M T Greco
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.